BRIEF FDA Grants Priority Review For Lilly\'s Verzenio

Oct 12 (Reuters) - Eli Lilly And Co:

* FDA grants priority review for potential new indication for Lilly’s verzenio (abemaciclib) as initial treatment of advanced breast cancer

* Eli Lilly And Co - ‍FDA’s goal is to take action within eight months of receiving an application, compared with standard review timeframe of 12 months​ Source text for Eikon: Further company coverage:

Source : http://www.reuters.com/article/brief-fda-grants-priority-review-for-lil/brief-fda-grants-priority-review-for-lillys-verzenio-idUSASB0BMTW?feedType=RSS

BRIEF-FDA grants priority review for Lilly's verzenio
FDA grants priority review for Lilly's Verzenio as initial treatment of advanced breast cancer
FDA Grants Priority Review for Potential New Indication for Lill - KAIT Jonesboro, AR - Region 8 News, weather, sports
FDA Grants Priority Review for Potential New Indication for Lill - KUSI News - San Diego, CA
FDA Grants Priority Review for Potential New Indication for Lill - Spokane, North Idaho News & Weather KHQ.com
Eli Lilly and : Correction to Eli Lilly CFO Article https://t.co/g7t3ErBMHX
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer
[LIMITED STOCK!] Related eBay Products